Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
10.3904/kjim.2014.29.2.246
- Author:
Ah Young LEEM
1
;
Han Sang KIM
;
Byung Woo YOO
;
Beo Deul KANG
;
Min Hwan KIM
;
Sun Young RHA
;
Hyo Song KIM
Author Information
1. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. HYOSONG77@yuhs.ac
- Publication Type:Case Reports ; Review
- Keywords:
Ifosfamide;
Fanconi syndrome;
Diabetes insipidus
- MeSH:
Acidosis/chemically induced;
Antineoplastic Agents, Alkylating/*adverse effects;
Chemotherapy, Adjuvant;
Diabetes Insipidus/*chemically induced/diagnosis/therapy;
Fanconi Syndrome/*chemically induced/diagnosis/therapy;
Fatal Outcome;
Histiocytoma, Malignant Fibrous/*drug therapy/pathology;
Humans;
Ifosfamide/*adverse effects;
Male;
Middle Aged;
Neoadjuvant Therapy/*adverse effects;
Time Factors
- From:The Korean Journal of Internal Medicine
2014;29(2):246-249
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ifosfamide-induced Fanconi syndrome is a rare complication that typically occurs in young patients due to a cumulative dose of ifosfamide > 40-60 g/m2, a reduction in kidney mass, or concurrent cisplatin treatment. It is usually characterized by severe and fatal progression accompanied by type II proximal renal tubular dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and metabolic acidosis. Diabetes insipidus is also a rare complication of ifosfamide-induced renal disease. We herein describe a case involving a 61-year-old man who developed ifosfamide-induced Fanconi syndrome accompanied by diabetes insipidus only a few days after the first round of chemotherapy. He had no known risk factors. In addition, we briefly review the mechanisms and possible therapeutic options for this condition based on other cases in the literature. Patients who receive ifosfamide must be closely monitored for renal impairment to avoid this rare but fatal complication.
